United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime 500 mg - cefotaxime for injection usp is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. - lower respiratory tract infections , including pneumonia, caused bystreptococcus pneumoniae (formerlydiplococcus pneumoniae ),streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g.,enterococcus faecalis ),staphylococcus aureus (penicillinase and non-penicillinase producing),escherichia coli ,klebsiella species,haemophilus influenzae (including ampicillin resistant strains),haemophilus parainfluenzae ,proteus mirabilis ,serratia marcescens *,enterobacter species, indole positiveproteus andpseudomonas species (includingp. aeruginosa ). - genitourinary infections . urinary tract infections caused byenterococcus species,staphylococcus epidermidis ,staphylococcus aureus *, (penicillinase and non-penicillinase producing),citrobacter species,enterobacter species,escherichia coli ,kl

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 250mg - cefotaxime (cefotaxime sodium) 250mg - third generation cephalosporins

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 500mg - cefotaxime (cefotaxime sodium) 500mg - third generation cephalosporins

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 1.0g - cefotaxime (cefotaxime sodium) 1.0g - third generation cephalosporins

Canada - English - Health Canada

hospira healthcare ulc - cefotaxime (cefotaxime sodium) - powder for solution - 2.0g - cefotaxime (cefotaxime sodium) 2.0g - third generation cephalosporins

Malta - English - Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - cefotaxime sodium - powder for solution for injection/infusion - cefotaxime sodium 500/2.2 mci/ml - antibacterials for systemic use

Malta - English - Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - cefotaxime sodium - solution for injection/infusion - cefotaxime sodium 1/4.4 g/ml - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cefotaxime sodium, quantity: 2.096 g - injection, powder for - excipient ingredients: - indications: cefotaxime is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms: infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta lactamase producing strains of n.gonorrhoeae). ear, nose and throat infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates) pending the availabiliy of culture and sensitivity results. in adults, the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram negative enteric bacilli. cefotaxime may be used for the prevention of post-operative infe

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefotaxime sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefotaxime sodium -